|
Product class:
|
Medicinal product with marketing authorization
|
|
Medicinal product class:
|
Human medicine
|
|
Name of medicinal product:
|
OGLUO
|
|
Active substances:
|
|
|
ATC code:
|
H04AA01
|
|
Dosage form:
|
solution for injection in pre-filled pen
|
|
Strength:
|
0,5mg
|
|
Legal status for supply*:
|
Subject to medicinal prescription
|
|
Summary of product characteristics (SPC):
|
|
|
Package information leaflet (PIL):
|
EST
|
|
Labelling:
|
|
|
Indication:
|
Ogluo is indicated for the treatment of severe hypoglycaemia in adults, adolescents, and children aged
2 years and over with diabetes mellitus.
|
|
Safety features:
|
Yes
|
|
Marketing authorization holder:
|
Tetris Pharma B.V.
|
|
Marketing authorization number:
|
EU/1/20/1523
|
|
Marketing authorization issued on:
|
11 February 2021
|
|
Marketing authorization expires on:
|
17 February 2026
|
|
Marketing authorization procedure type:
|
Centralised
|
|
Assessment report:
|
|
|
Package code
|
Name of medicinal product
|
Dosage form
|
Package
|
Legal status
|
Reimbursements
|
Reference price
|
Last imported
|
PƤritolumaa
|
Additional information
|
|
1841813
|
OGLUO
|
solution for injection in pre-filled pen
|
0,5mg 1TK
|
Prescription
|
|
|
|
|
|
|
1841824
|
OGLUO
|
solution for injection in pre-filled pen
|
0,5mg 2TK
|
Prescription
|
|
|
|
|
|
Legal status for supply – medicinal product on medical prescription or not subject to medical prescription